Logo image of MDGS

MEDIGUS LTD - SPON ADR (MDGS) Stock Fundamental Analysis

NASDAQ:MDGS - Nasdaq - US58471G4091 - ADR - Currency: USD

2.36  +0.18 (+8.28%)

After market: 2.6 +0.24 (+10.17%)

Fundamental Rating

2

Overall MDGS gets a fundamental rating of 2 out of 10. We evaluated MDGS against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of MDGS have multiple concerns. MDGS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDGS had negative earnings in the past year.
In the past year MDGS has reported a negative cash flow from operations.
In the past 5 years MDGS reported 4 times negative net income.
In the past 5 years MDGS always reported negative operating cash flow.
MDGS Yearly Net Income VS EBIT VS OCF VS FCFMDGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

1.2 Ratios

With a Return On Assets value of -15.49%, MDGS perfoms like the industry average, outperforming 57.95% of the companies in the same industry.
MDGS has a Return On Equity (-41.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROIC N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
MDGS Yearly ROA, ROE, ROICMDGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

1.3 Margins

MDGS has a worse Gross Margin (14.92%) than 81.03% of its industry peers.
In the last couple of years the Gross Margin of MDGS has declined.
The Profit Margin and Operating Margin are not available for MDGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
MDGS Yearly Profit, Operating, Gross MarginsMDGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

MDGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDGS has been reduced compared to 1 year ago.
Compared to 1 year ago, MDGS has a worse debt to assets ratio.
MDGS Yearly Shares OutstandingMDGS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
MDGS Yearly Total Debt VS Total AssetsMDGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.19, we must say that MDGS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MDGS (-0.19) is comparable to the rest of the industry.
MDGS has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.11, MDGS perfoms like the industry average, outperforming 55.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACC7.41%
MDGS Yearly LT Debt VS Equity VS FCFMDGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 1.30 indicates that MDGS should not have too much problems paying its short term obligations.
MDGS's Current ratio of 1.30 is on the low side compared to the rest of the industry. MDGS is outperformed by 87.69% of its industry peers.
A Quick Ratio of 1.23 indicates that MDGS should not have too much problems paying its short term obligations.
MDGS has a worse Quick ratio (1.23) than 75.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.23
MDGS Yearly Current Assets VS Current LiabilitesMDGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MDGS have decreased strongly by -116.00% in the last year.
The Revenue has grown by 158.35% in the past year. This is a very strong growth!
Measured over the past years, MDGS shows a very strong growth in Revenue. The Revenue has been growing by 187.58% on average per year.
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDGS Yearly Revenue VS EstimatesMDGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MDGS Yearly EPS VS EstimatesMDGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDGS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDGS Price Earnings VS Forward Price EarningsMDGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGS Per share dataMDGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

MDGS has a Yearly Dividend Yield of 29.82%, which is a nice return.
The stock price of MDGS dropped by -30.59% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
MDGS's Dividend Yield is rather good when compared to the industry average which is at 1.87. MDGS pays more dividend than 100.00% of the companies in the same industry.
MDGS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
Industry RankSector Rank
Dividend Yield 29.82%

5.2 History

MDGS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MDGS Yearly Dividends per shareMDGS Yearly Dividends per shareYearly Dividends per share 2022 1 2 3 4

5.3 Sustainability

The earnings of MDGS are negative and hence is the payout ratio. MDGS will probably not be able to sustain this dividend level.
DP-31.57%
EPS Next 2YN/A
EPS Next 3YN/A
MDGS Yearly Income VS Free CF VS DividendMDGS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

More info and screens

MEDIGUS LTD - SPON ADR

NASDAQ:MDGS (4/17/2024, 8:12:04 PM)

After market: 2.6 +0.24 (+10.17%)

2.36

+0.18 (+8.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-23 2022-09-23/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-99.92%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 29.82%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-31.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 6.13
EV/EBITDA N/A
EPS(TTM)-6.98
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS58.21
BVpS16.77
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.92%
FCFM N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.17%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.23
Altman-Z -0.19
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)598.88%
Cap/Depr(5y)379.57%
Cap/Sales(3y)37.08%
Cap/Sales(5y)27.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.17%
OCF growth 3YN/A
OCF growth 5YN/A